In a recently published literature review, researchers examined the potential impact of advanced sequences, scanners, patient preparation and AI on image quality for prostate MRI exams.
Does the combination of deep learning reconstruction (DLR) and diffusion-weighted imaging (DWI) have an impact in prostate cancer (PCa) detection on magnetic resonance imaging (MRI)? Does pre-MRI enema use facilitate improved diagnosis of clinically significant PCa (csPCa)? Does the PI-QUAL scoring system bolster sensitivity for extraprostatic extension (EPE)?
In a new literature review, recently published in the Journal of Magnetic Resonance Imaging, researchers considered those questions and many more in their examination of prostate MRI imaging quality. Here are seven takeaways from their review.
1. With the exception of cases involving metallic devices and implants, 3T MRI scanners are preferred over 1.5T scanners, according to PI-RADS guidelines. Researchers have also noted that 3T MRI offers better signal-to-noise (SNR) and contrast-to-noise (CNR) ratios as well as subjective image quality. However, the authors also pointed out that a 2022 meta-analysis and other research have shown no statistically significant difference between 1.5T and 3T MRI for the diagnosis of PCa.
2. While the review authors emphasized caution with the use of endorectal coils (ERCs) due to possible supplementary artifacts, they noted three studies that demonstrated higher sensitivity for PCa detection, including one study showing a 31 percent increase in the diagnosis of clinically significant PCa (csPCa) with the use of ERCs. However, the review authors said other research on PCa detection with ERCs has been mixed and acknowledged a similar variety of findings when comparing 1.5 T MRI plus ERC to 3 T MRI.
3. In comparing three-dimensional weighted imaging (3D T2-WI) to two-dimensional weighted imaging (2D T2-WI), researchers have noted that 3D T2-WI offers better artifact assessment as well as improved visualization of internal prostate anatomy and the genitourinary diaphragm in comparison to 2D T2-WI. However, the review authors pointed out that 2D T2-WI provides superior image sharpness, better SNR in the peripheral zone and visualization of seminal vesicles. Multiple studies have demonstrated no significant differences between 3D T2-WI and 2D T2-WI for diagnosing or staging PCa, according to the review authors.
4. In regard to the use of deep learning reconstruction (DLR) with diffusion-weighted imaging (DWI), researchers have noted improved SNR and CNR but only one out of four studies have found improved subjective image quality with DLR for prostate imaging. For detection of PCa lesions and extraprostatic extension (EPE), the review authors pointed out no differences between conventional MRI and the combination of DLR and DWI.
5. Researchers have found that use of the PI-QUAL score, a standardized system for assessing the quality of multiparametric MRI (mpMRI), has facilitated improved detection of EPE. Specifically, the review authors noted research that demonstrated higher EPE sensitivity and specificity with PI-QUAL > 4 in comparison to PI-QUAL < 3. However, they also acknowledged that two separate studies, published in 2023, found no significant difference between the aforementioned PI-QUAL quality assessments in detecting EPE or staging PCa.
(Editor's note: For related content on prostate cancer imaging, click here.)
6. Do anti-peristaltic medications have an impact on prostate MRI quality? The review authors noted mixed evidence on the use of hyoscine butylbromide. One study noted this agent had no impact on motion artifacts, image quality or visualization of prostatic structures. The researchers added that a 2023 study assessment of intramuscular glucagon for T2-WI imaging revealed no significant impact for image quality nor detection of csPCa.
7. In regard to the use of enemas prior to DWI MRI, the review authors noted reports of higher image quality and less severe artifacts but acknowledged another study in which radiologists saw less distortion on DWI, but urologists did not. A 2022 study found that use of pre-MRI enema had no difference upon csPCa detection, according to the review authors.
(Editor's note: For related content, see "Can a Deep Learning Algorithm Enhance Detection of Prostate Cancer Recurrence with BIparametric MRI?," "Prostate MRI Study Finds Little Difference Between PI-RADS 2.0 and PI-RADS 2.1" and "Study: 66 Percent of Men with Positive MRI for Prostate Cancer Had Normal PSA Levels.")
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Can AI Enhance PET/MRI Assessment for Extraprostatic Tumor Extension in Patients with PCa?
December 17th 2024The use of an adjunctive machine learning model led to 17 and 21 percent improvements in the AUC and sensitivity rate, respectively, for PET/MRI in diagnosing extraprostatic tumor extension in patients with primary prostate cancer.
What SPECT/CT May Reveal About Early Treatment Response for Pluvicto in Patients with mCRPC
November 13th 2024Researchers found that new prostate lesion detection on SPECT/CT at the beginning of a second cycle of 177 Lu-PSMA-617 for mCRPC was associated with an over sevenfold higher mortality risk.
AI Segmentation, Intraprostatic Tumor Volume and Metastases: What a New mpMRI Study Reveals
October 29th 2024For patients who received radiotherapy for localized prostate cancer, total intraprostatic tumor volume derived from AI segmentation had a 10 percent higher AUC for predicting seven-year metastases in comparison to a risk model from the National Comprehensive Cancer Network (NCCN).